QIAGEN Expands Master Collaboration Agreement With AstraZeneca's Future Therapies To Develop And Validate A Genotyping Assay Using Co's Syndromic Testing Platform QIAstat-Dx
QIAGEN Expands Master Collaboration Agreement With AstraZeneca's Future Therapies To Develop And Validate A Genotyping Assay Using Co's Syndromic Testing Platform QIAstat-Dx
QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))))) today announced the expansion of its Master Collaboration Agreement with AstraZeneca to develop and commercialize companion diagnostics (CDx) for AstraZeneca's future therapies being developed to address chronic diseases.
Qiagen（纽交所：QGEN，法兰克福证券交易所：QIA）今天宣布，将扩大与阿斯利康的主要合作协议，共同开发和商业化阿斯利康未来用于治疗慢性疾病的伴随诊断（CDx）。
Under the agreement, QIAGEN will develop and validate a genotyping assay using QIAGEN's syndromic testing platform QIAstat-Dx. The test will enable specialty care providers to potentially perform genotyping whilst patients are undergoing routine clinical examination, thus enabling fast decision making for potential suitability for AstraZeneca's genomically targeted medicines.
根据协议，Qiagen将利用Qiagen的综合测试平台QIAstat-Dx开发和验证一种基因型鉴定测定方法。该测定方法将使专科医疗提供者能够在患者进行常规临床检查时进行基因型鉴定，从而能够快速决策是否适合使用阿斯利康的基因组靶向药物。